{"id":53163,"date":"2023-01-21T15:02:37","date_gmt":"2023-01-21T14:02:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/wugen-presents-data-on-wu-nk-101-in-combination-with-cetuximab-in-preclinical-models-of-advanced-colorectal-cancer-crc-at-asco-gastrointestinal-cancers-symposium\/"},"modified":"2023-01-21T15:02:37","modified_gmt":"2023-01-21T14:02:37","slug":"wugen-presents-data-on-wu-nk-101-in-combination-with-cetuximab-in-preclinical-models-of-advanced-colorectal-cancer-crc-at-asco-gastrointestinal-cancers-symposium","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/wugen-presents-data-on-wu-nk-101-in-combination-with-cetuximab-in-preclinical-models-of-advanced-colorectal-cancer-crc-at-asco-gastrointestinal-cancers-symposium\/","title":{"rendered":"Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium"},"content":{"rendered":"
\n

\n— WU-NK-101 overcomes limitations encountered with other adoptive cell therapies in solid tumors —<\/i>\n<\/p>\n

\n— WU-NK-101 exhibited robust trafficking, intra-tumor infiltration, and persistence in xenograft tumor models which were further enhanced when combined with monoclonal antibodies (mAbs) <\/i>—<\/i>\n<\/p>\n

\n— WU-NK-101 maintained robust cytotoxicity in the tumor microenvironment (TME), including against primary CRC samples in the \u201cnative\u201d TME —<\/i>\n<\/p>\n

\n— WU-NK-101 demonstrated superior anti-tumor efficacy against colorectal cancer (CRC) tumor cell lines in vivo and in vitro compared to cetuximab (Ctx) monotherapy; efficacy was further augmented when deployed in combination —<\/i>\n<\/p>\n

\n—<\/i> Data support clinical development of WU-NK-101 for CRC and other solid tumor indications —<\/i>\n<\/p>\n

ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc.<\/a>, a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented preclinical data on WU-NK-101, the company\u2019s lead memory natural killer (NK) cell therapy product, in combination with cetuximab (Ctx), at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place January 19-21, 2023, in San Francisco, California.\n<\/p>\n

<\/a><\/p>\n

\n\u201cOur best-in-class memory NK cell platform is uniquely designed to have broad applications across solid and liquid tumors,\u201d said Jan Davidson-Moncada, M.D., Ph.D., Chief Medical Officer of Wugen.\u201cWU-NK-101 has a unique CIML phenotype with enhanced metabolic fitness\/flexibility and decreased susceptibility to immunosuppression\u2014key properties that in combination with these data, build our conviction in the development trajectory for WU-NK-101 as a novel treatment for solid tumor cancers. We plan to initiate a first-in-human study of WU-NK-101 in combination with cetuximab for CRC in addition to SCCHN later this year.\u201d\n<\/p>\n

\nToday\u2019s presentation highlighted the following:\n<\/p>\n